Autori: Chong LO
Naslov | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome (Meeting Abstract) |
Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Z Nagarkar R Chawla T Chong LO Nixon B Yavrom S Ede NJ Wiedermann Ursula |
Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 2, str. S864-S864 |
Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |